Practical applications in immunohistochemistry: Evaluation of rejection and infection in organ transplantation

Archives of Pathology and Laboratory Medicine

Volumn 140, Issue 9, 2016, Pages 910-925

  Troxell, Megan L ^a   Lanciault, Christian ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

ADVERSE EFFECTS; ALLOGRAFT; COMPLICATION; GRAFT REJECTION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; ORGAN TRANSPLANTATION; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; VIROLOGY; VIRUS; VIRUS INFECTION;

ALLOGRAFTS; COMPLEMENT C4B; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; ORGAN TRANSPLANTATION; PATHOLOGY, CLINICAL; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; VIRUS DISEASES; VIRUSES;

EID: 84984861253     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2015-0275-CP     Document Type: Article

References (165)

1. Nickeleit V, Mengel M, Colvin RB. Renal transplant pathology. In: Jennette JC, Olson JL, Silva FG, D'Agati VD, eds. Heptinstall's Pathology of the Kidney. 7th ed. Philadelphia, PA: Wolters-Kluwer; 2015:1321-1460.
2. Delos Santos R, Langewisch E, Norman DJ. Immunological assessment of the transplant patient. In: Weir MR, Lerma, EV, eds. Kidney Transplantation: Practical Guide to Management. New York, NY: Springer Science+Business Media; 2014:23-35.
3. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant. 2007;7(2):408-415.
4. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation. 2003;75(7):1034-1040.
5. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 1993;43(6):1333-1338.
6. Feucht HE. Complement C4d in graft capillaries-the missing link in the recognition of humoral alloreactivity. Am J Transplant. 2003;3(6):646-652.
7. Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int. 2012;81(7):628-639.
8. Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant 2003(11); 18:2232-2239.
9. Böhmig G, Regele H. Diagnosis and treatment of antibody-mediated kidney allograft rejection. Transpl Int. 2003;16(11):773-787.
10. Racusen LC, Colvin RB, Solez K, et al; Banff meeting report writing committee. Antibody-mediated rejection criteria-an addition to the Banff'97 classification of renal allograft rejection. Am J Transplant 2003;3(6):708-714.
11. Haas M, Sis B, Solez K, et al; Banff meeting report writing committee. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions [published correction appears in Am J Transplant. 2015;15(10):2784]. Am J Transplant. 2014;14(2):272-283.
12. Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant. 2011;11(9):1792-1802.
13. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32(12):1147-1162.
14. Berry G, Burke M, Andersen C, et al. Pathology of pulmonary antibodymediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant. 2013;32(1):14-21.
15. Nadasdy GM, Bott C, Cowden D, Pelletier R, Ferguson R, Nadasdy T. Comparative study for the detection of peritubular capillary C4d deposition in human renal allografts using different methodologies. Hum Pathol. 2005;36(11):1178-1185.
16. Troxell ML, Weintraub LA, Higgins JP, Kambham N. Comparison of C4d immunostaining methods in renal allograft biopsies. Clin J Am Soc Nephrol. 2006;1(3):583-591.
17. Seemayer CA, Gaspert A, Nickeleit V, et al. C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques. Nephrol Dial Transplant 2007;22(2):568-576.
18. Batal I, Girnita A, Zeevi A, Mihatsch MJ. Clinical significance of the distribution of C4d deposits in different anatomic compartments of the allograft kidney. Mod Pathol. 2008;21(12):1490-1498.
19. Ludovico-Martins H, Silva C, Teodoro WR, Martini Filho D, Noronha IL. Analysis of different staining techniques for c4d detection in renal allograft biopsies. Transplant Proc. 2009;41(3):862-865.
20. Feucht HE, Mihatsch MJ. Diagnostic value of C4d in renal biopsies. Curr Opin Nephrol Hypertens. 2005;14(6):592-598.
21. Jen KY, Nguyen TB, Vincenti FG, Laszik ZG. C4d/CD34 doubleimmunofluorescence staining of renal allograft biopsies for assessing peritubular capillary C4d positivity. Mod Pathol. 2012;25(3):434-438.
22. Kuypers DR, Lerut E, Evenepoel P, Maes B, Vanrenterghem Y, Van Damme B. C3D deposition in peritubular capillaries indicates a variant of acute renal allograft rejection characterized by a worse clinical outcome. Transplantation. 2003;76(1):102-108.
23. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant. 2006;6(8):1829-1840.
24. Herman J, Lerut E, Van Damme-Lombaerts R, Emonds MP, Van Damme B. Capillary deposition of complement C4d and C3d in pediatric renal allograft biopsies. Transplantation. 2005;79(10):1435-1440.
25. Gierej B, Górnicka B, Wasiutyński A. Role of C3d and C4d complement fragments in the diagnostics of acute allograft rejection after transplantations. Ann Transplant. 2009;14(4):61-70.
26. Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant. 2009;9(9):2075-2084.
27. Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int. 2012;25(6):623-632.
28. Colvin MM, Cook JL, Chang P, et al; for American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2015;131(18):1608-1639.
29. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complementsplit products in kidney allografts with cell-mediated rejection. Clin Exp Immunol. 1991;86(3):464-470.
30. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int. 2001;59(1):334-341.
31. Regele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant. 2001;16(10):2058-2066.
32. Regele H, Böhmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol. 2002;13(9):2371-2380.
33. Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol. 2002:13(4):1091-1099.
34. Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol. 2002;13(1):242-251.
35. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol. 2001;12(3):574-582.
36. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation, II: morphology, immunopathology, and pathologic classification. J Am Soc Nephrol. 2002:13(3):779-787.
37. Herzenberg AM, Gill JS, Djurdjev O, Magil AJ. C4d deposition in acute rejection: an independent long term prognostic factor. J Am Soc Nephrol. 2002;13:234-241.
38. Kawamura N, Tomita M, Hasegawa M, et al. Complement C4d deposition in transplanted kidneys: preliminary report on long-term graft survival. Clin Transplant. 2005;19(suppl 14):27-31.
39. Lorenz M, Regele H, Schillinger M, et al. Risk factors for capillary C4d deposition in kidney allografts: evaluation of a large study cohort. Transplantation. 2004;78(3):447-452.
40. Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens. 2002;11(6):609-618.
41. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753-760.
42. Sis B, Mengel M, Haas M, et al. Banff'09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010;10(3):464-471.
43. Kikić Ž, Kainz A, Kozakowski N, et al. Capillary C4d and kidney allograft outcome in relation to morphologic lesions suggestive of antibody-mediated rejection. Clin J Am Soc Nephrol. 2015;10(8):1435-1443.
44. Mengel M, Sis B, Haas M, et al; Banff meeting report writing committee. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant. 2012;12(3):563-570.
45. Koller H, Steurer W, Mark W, et al. Clearance of C4d deposition after successful treatment of acute humoral rejection in follow-up biopsies: a report of three cases. Transpl Int. 2004;17(4):177-181.
46. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation. 2003;76(10):1519-2155.
47. Bracamonte E, Leca N, Smith KD, et al. Tubular basement membrane immune deposits in association with BK polyomavirus nephropathy. Am J Transplant. 2007;7:1552-1560.
48. Batal I, Zainah H, Stockhausen S, et al. The significance of renal C4d staining in patients with BK viruria, viremia, and nephropathy. Mod Pathol. 2009;22(11):1468-1476.
49. Couzi L, Perera R, Manook M, et al. Incidence and outcome of C4d staining with tubulointerstitial inflammation in blood group-incompatible kidney transplantation. Transplantation. 2015;99(7):1487-1494.
50. Mengel M, Chan S, Climenhaga J, et al. Banff initiative for quality assurance in transplantation (BIFQUIT): reproducibility of C4d immunohistochemistry in kidney allografts. Am J Transplant. 2013;13(5):1235-1245.
51. Drachenberg CB, Odorico J, Demetris AJ, et al. Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. Am J Transplant. 2008;8(6):1237-1249.
52. Troxell ML, Koslin DB, Norman D, Rayhill S, Mittalhenkle A. Pancreas allograft rejection: analysis of concurrent renal allograft biopsies and posttherapy follow-up biopsies. Transplantation. 2010;90(1):75-84.
53. Patil DT, Yerian LM. Pancreas transplant: recent advances and spectrum of features in pancreas allograft pathology. Adv Anat Pathol. 2010;17(3):202-208.
54. Rangel EB, Malheiros DM, de Castro MC, et al. Antibody-mediated rejection (AMR) after pancreas and pancreas-kidney transplantation. Transpl Int. 2010;23(6):602-610.
55. Rogers J, Farney AC, Orlando G, et al. Pancreas transplantation: the Wake Forest experience in the new millennium. World J Diabetes. 2014;5(6):951-961.
56. Melcher ML, Olson JL, Baxter-Lowe LA, Stock PG, Posselt AM. Antibodymediated rejection of a pancreas allograft. Am J Transplant. 2006;6(2):423-428.
57. Carbajal R, Karam G, Renaudin K, et al. Specific humoral rejection of a pancreas allograft in a recipient of pancreas after kidney transplantation. Nephrol Dial Transplant. 2007;22(3):942-944.
58. Prikis M, Norman D, Rayhill S, Olyaei A, Troxell M, Mittalhenkle A. Preserved endocrine function in a pancreas transplant recipient with pancreatic panniculitis and antibody-mediated rejection. Am J Transplant. 2010;10(12):2717-2722.
59. Torrealba JR, Samaniego M, Pascual J, et al. C4d-positive interacinar capillaries correlates with donor-specific antibody-mediated rejection in pancreas allografts. Transplantation. 2008;86(12):1849-1856.
60. Niederhaus SV, Leverson GE, Lorentzen DF, et al. Acute cellular and antibody-mediated rejection of the pancreas allograft: incidence, risk factors and outcomes. Am J Transplant. 2013;13(11):2945-2955.
61. de Kort H, Munivenkatappa RB, Berger SP, et al. Pancreas allograft biopsies with positive c4d staining and anti-donor antibodies related to worse outcome for patients. Am J Transplant. 2010;10(7):1660-1667.
62. de Kort H, Mallat MJ, van Kooten C, et al. Diagnosis of early pancreas graft failure via antibody-mediated rejection: single-center experience with 256 pancreas transplantations. Am J Transplant. 2014;14(4):936-942.
63. Munivenkatappa RB, Philosophe B, Papadimitriou JC, Drachenberg CB. Interacinar c4d staining in pancreas allografts. Transplantation. 2009;88(1):145-146.
64. Drachenberg CB, Troxell ML, Papadimitriou JC. Pancreas allograft pathology. In: Molmenti EP, Dowling MJ, eds. Kidney and Pancreas Transplantation. 1st ed. New Delhi, India: Jaypee Brothers Medical Publishers. 2015;523-538.
65. Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant. 1989;8(6):430-443.
66. Fishbein GA, Fishbein MC. Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Hum Immunol. 2012;73(12):1213-1217.
67. Berry GJ, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant. 2011;30(6):601-611.
68. Berry GJ. Antibody-mediated rejection of the cardiac allograft: where do we stand in 2012? Curr Opin Organ Transplant. 2012;17(3):303-308.
69. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al; Consensus Conference Participants. Report from a consensus conference on antibodymediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30(3):252-269.
70. Fedrigo M, Gambino A, Tona F, et al. Can C4d immunostaining on endomyocardial biopsies be considered a prognostic biomarker in heart transplant recipients [published correction appears in Transplantation. 2011;91(1): 135]? Transplantation. 2010;90(7):791-798.
71. Chantranuwat C, Qiao JH, Kobashigawa J, Hong L, Shintaku P, Fishbein MC. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence. Appl Immunohistochem Mol Morphol. 2004;12(2):166-171.
72. Miller DV, Roden AC, Gamez JD, Tazelaar HD. Detection of C4d deposition in cardiac allografts: a comparative study of immunofluorescence and immunoperoxidase methods. Arch Pathol Lab Med. 2010;134(11):1679-1684.
73. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al; Consensus Conference Participants. Report from a consensus conference on antibodymediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30(3):252-269.
74. Yerly P, Rotman S, Nobile A, et al. Time-dependent specificity of immunopathologic (C4d-CD68) and histologic criteria of antibody-mediated rejection for donor-specific antibodies and allograft dysfunction in heart transplantation. Transplantation. 2015;99(3):586-593.
75. Westall GP, Snell GI. Antibody-mediated rejection in lung transplantation: fable, spin, or fact? Transplantation. 2014;98(9):927-930.
76. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007;26(12):1229-1242.
77. Wallace WD, Weigt SS, Farver CF. Update on pathology of antibodymediated rejection in the lung allograft. Curr Opin Organ Transplant. 2014;19(3):303-308.
78. Westall GP, Snell GI, McLean C, Kotsimbos T, Williams T, Magro C. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant. 2008;27(7):722-728.
79. Roberts JA, Barrios R, Cagle PT, et al. The presence of anti-HLA donorspecific antibodies in lung allograft recipients does not correlate with C4d immunofluorescence in transbronchial biopsy specimens. Arch Pathol Lab Med. 2014;138(8):1053-1058.
80. De Nicola MM, Weigt SS, Belperio JA, Reed EF, Ross DJ, Wallace WD. Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant. 2013;32(3):326-332.
81. Westall GP, Paraskeva MA, Snell GI. Antibody-mediated rejection. Curr Opin Organ Transplant. 2015;20(5):492-497.
82. Roden AC, Maleszewski JJ, Yi ES, et al. Reproducibility of complement 4d deposition by immunofluorescence and immunohistochemistry in lung allograft biopsies. J Heart Lung Transplant. 2014;33(12):1223-1232.
83. Hübscher SG. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant. 2012;17(3):280-286.
84. Taner T, Stegall MD, Heimbach JK. Antibody-mediated rejection in liver transplantation: current controversies and future directions. Liver Transpl. 2014;20(5):514-527.
85. Navarro V, Herrine S, Katopes C, Colombe B, Spain CV. The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: an analysis of the OPTN database. Liver Transpl. 2006;12(4):652-658.
86. Demetris AJ, Murase N, Nakamura K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis. 1992;12(1):51-59.
87. Lunz, J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can c4d stains help in monitoring? Am J Transplant. 2012;12(1):171-182.
88. Sakashita H, Haga H, Ashihara E, et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol. 2007;20(6):676-684.
89. Bellamy COC, Herriot MM, Harrison DJ, Bathgate AJ. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology. 2007;50(6):739-749.
90. Haga H, Egawa H, Fujimoto, Y, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl. 2006;12(3):457-464.
91. Ali S, Ormsby A, Shah V, et al. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transpl Immunol. 2012;26(1):62-69.
92. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant. 2011;11(3):500-510.
93. Kozlowski T, Andreoni, K, Schmitz J, Hayashi PH, Nickeleit V. Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts. Liver Transpl. 2012;18(6):641-658.
94. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibodymediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl. 2011;17(4):357-368.
95. Dugum M, Askar M, Pai RK, et al. Re-examination of sinusoidal deposition of complement 4d in liver allografts: experience from a single institution. Int J Clin Exp Pathol. 2014;7(2):784-791.
96. Bellamy COC. Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: applications and pitfalls [comment]. Liver Transpl. 2011;17(7):747-750.
97. Bouron-Dal Soglio D, Rougemont AL, Herzog D, Soucy G, Alvarez F, Fournet JC. An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases. Hum Pathol. 2008;39(7):1103-1110.
98. Neil DAH, Hübscher SG. Current views on rejection pathology in liver transplantation. Transpl Int. 2010;23(10):971-983.
99. Sund S, Reisaeter AV, Scott H, Mollnes TE, Hovig T. Glomerular monocyte/macrophage influx correlates strongly with complement activation in 1-week protocol kidney allograft biopsies. Clin Nephrol. 2004;62(2):121-130.
100. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int. 2005;68(4):1866-1874.
101. Fedrigo M, Feltrin G, Poli F, et al. Intravascular macrophages in cardiac allograft biopsies for diagnosis of early and late antibody-mediated rejection. J Heart Lung Transplant. 2013;32(4):404-409.
102. Xu L, Collins J, Drachenberg C, Kukuruga D, Burke A. Increased macrophage density of cardiac allograft biopsies is associated with antibodymediated rejection and alloantibodies to HLA antigens. Clin Transplant. 2014;28(5):554-560
103. Moal V, Zandotti C, Colson P. Emerging viral diseases in kidney transplant recipients. Rev Med Virol. 2013;23(1):50-69.
104. Eyzaguirre E, Haque AK. Application of immunohistochemistry to infections. Arch Pathol Lab Med. 2008;132(3):424-431.
105. Ernst J, Sauerbrei A, Krumbholz A, et al. Multiple viral infections after haploidentical hematopoietic stem cell transplantation in a child with acute lymphoblastic leukemia. Transpl Infect Dis. 2012;14(5):E82-E88.
106. Dingle TC, Butler-Wu SM. MALDI-TOF mass spectrometry for microorganism identification. Clin Lab Med. 2013;33(3):589-609.
107. Woo PC, Lau SK, Teng JL, Tse H, Yuen KY. Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. Clin Microbiol Infect. 2008;14(10):908-934.
108. Kotton CN, Kumar D, Caliendo AM, et al; for Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333-360.
109. Florescu DF, Hoffman JA; AST Infectious Diseases Community of Practice. Adenovirus in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):206-211.
110. Humar A, Michaels M; for AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262-274.
111. Eid AJ, Chen SF; AST Infectious Diseases Community of Practice. Human parvovirus B19 in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):201-205.
112. Martina MN, Cervera C, Esforzado N, et al. Toxoplasma gondii primary infection in renal transplant recipients: two case reports and literature review. Transpl Int. 2011;24(1):e6-e12.
113. Bruno B, Zager RA, Boeckh MJ, et al. Adenovirus nephritis in hematopoietic stem-cell transplantation. Transplantation. 2004;15;77(7):1049-1057.
114. Fowler CJ, Dunlap J, Troyer D, Stenzel P, Epner E, Maziarz RT. Lifethreatening adenovirus infections in the setting of the immunocompromised allogeneic stem cell transplant patients. Adv Hematol. 2010;2010:601548.
115. Storsley L, Gibson IW. Adenovirus interstitial nephritis and rejection in an allograft. J Am Soc Nephrol. 2011;22(8):1423-1427.
116. Nickeleit V, Singh HK, Mihatsch MJ. Latent and productive polyomavirus infections of renal allografts. In: Ahsan N, ed. Polyomaviruses and Human Diseases. New York, NY: Springer; 2006:190-200.
117. Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation. 2009;87(5):621-630.
118. Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):179-188.
119. Nickeleit V, Mihatsch MJ. Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat. Transpl Int. 2006;19(12):960-973.
120. Singh HK, Nickeleit V. Polyomaviruses and disease: is there more to know than viremia and viruria? Curr Opin Organ Transplant. 2015;20(3):348-358.
121. Randhawa P, Baksh F, Aoki N, Tschirhart D, Finkelstein S. JC virus infection in allograft kidneys: analysis by polymerase chain reaction and immunohistochemistry. Transplantation. 2001;71(9):1300-1303.
122. Sunden Y, Suzuki T, Orba Y, et al. Characterization and application of polyclonal antibodies that specifically recognize JC virus large T antigen. Acta Neuropathol. 2006;111(4):379-387.
123. Adam B, Randhawa P, Chan S, et al. Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): reproducibility of polyomavirus immunohistochemistry in kidney allografts. Am J Transplant. 2014;14(9):2137-2147.
124. Wang Z, Portier BP, Hu B, et al. Diagnosis of BK viral nephropathy in the renal allograft biopsy: role of fluorescence in situ hybridization. J Mol Diagn. 2012;14(5):494-500.
125. Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virusassociated interstitial nephritis in the allograft kidney. Transplantation. 1999;67(1):103-109.
126. Menter T, Mayr M, Schaub S, Mihatsch MJ, Hirsch HH, Hopfer H. Pathology of resolving polyomavirus-associated nephropathy. Am J Transplant. 2013;13(6):1474-1483.
127. Randhawa P. Incorporation of pathology and laboratory findings into management algorithms for polyomavirus nephropathy [comment]. Am J Transplant. 2013;13(6):1379-1381.
128. Fishman JA. Overview: cytomegalovirus and the herpesviruses in transplantation. Am J Transplant. 2013;13(suppl 3):1-8.
129. Razonable RR. Human herpesviruses 6, 7, and 8 in solid organ transplant recipients. Am J Transplant. 2013;13(suppl 3):67-77.
130. Grimaldi A, Barletta A, Rascente M, et al. Infectious complications in the renal transplant recipient. Transplant Proc. 2005;37(6):2502-2503.
131. Klassen DK, Drachenberg CB, Papadimitriou JC, et al. CMV allograft pancreatitis: diagnosis, treatment, and histological features. Transplantation. 2000;69(9):1968-1971.
132. Mills AM, Guo FP, Copland AP, Pai RK, Pinsky BA. A comparison of CMV detection in gastrointestinal mucosal biopsies using immunohistochemistry and PCR performed on formalin-fixed, paraffin-embedded tissue. Am J Surg Pathol. 2013;37(7):995-1000.
133. McCoy MH, Post K, Sen JD, et al. qPCR increases sensitivity to detect cytomegalovirus in formalin-fixed, paraffin-embedded tissue of gastrointestinal biopsies. Hum Pathol. 2014;45(1):48-53.
134. Lu DY, Qian J, Easley KA, Waldrop SM, Cohen C. Automated in situ hybridization and immunohistochemistry for cytomegalovirus detection in paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol. 2009;17(2):158-164.
135. Netchiporouk E, Tchervenkov J, Paraskevas S, Sasseville D, Billick R. Evaluation of herpes simplex virus infection morbidity and mortality in pancreas and kidney-pancreas transplant recipients. Transplant Proc. 2013;45(9):3343-3347.
136. Netchiporouk E, Tchervenkov J, Paraskevas S, Sasseville D, Billick R. Evaluation of varicella zoster virus infection morbidity and mortality in pancreas and kidney-pancreas transplant recipients. Transplant Proc. 2013;45(2):701-704.
137. Rodriguez-Moreno A, Sanchez-Fructuoso AI, Calvo N, et al. Varicella infection in adult renal allograft recipients: experience at one center. Transplant Proc. 2006;38(8):2416-2418.
138. Riediger C, Sauer P, Matevossian E, Müller MW, Büchler P, Friess H. Herpes simplex virus sepsis and acute liver failure. Clin Transplant. 2009;23(suppl 21):37-41.
139. Sato A, Amada N, Kikuchi H, Fukumori T, Haga I, Takahashi Y. Pneumonia due to varicella-zoster virus reinfection in a renal transplant recipient. Transplant Proc. 2009;41(9):3959-3961.
140. Elliott WC, Houghton DC, Bryant RE, Wicklund R, Barry JM, Bennett WM. Herpes simplex type 1 hepatitis in renal transplantation. Arch Intern Med. 1980;140(12):1656-1660.
141. Cunha BA, Eisenstein LE, Dillard T, Krol V. Herpes simplex virus (HSV) pneumonia in a heart transplant: diagnosis and therapy. Heart Lung. 2007;36(1):72-78.
142. Pietrucha-Dilanchian P, Tanawuttiwat T, Abbo L, et al. Fatal herpes simplex virus type 2 hepatitis in a heart transplant recipient: a case report and review of the literature. Transpl Infect Dis. 2013;15(3):E87-E96.
143. Ariza-Heredia EJ, Razonable RR. Human herpes virus 8 in solid organ transplantation. Transplantation. 2011;92(8):837-844.
144. Lebbe C, Porcher R, Marcelin AG, et al; Skin and Organ Transplantation Group of the French Society of Dermatology. Human herpesvirus 8 (HHV8) transmission and related morbidity in organ recipients. Am J Transplant. 2013;13(1):207-213.
145. Riva G, Luppi M, Barozzi P, Forghieri F, Potenza L. How I treat HHV8/KSHV-related diseases in posttransplant patients. Blood. 2012;120(20):4150-4159.
146. Patel S, Xiao P. Primary effusion lymphoma Arch Pathol Lab Med. 2013;137(8):1152-1154.
147. Xuan L, Jiang X, Sun J, et al. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation. Transplantation. 2013;96(6):560-566.
148. Liu QF, Fan ZP, Luo XD, Sun J, Zhang Y, Ding YQ. Epstein-Barr virusassociated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. Transpl Infect Dis. 2010;12(4):284-291.
149. Cesarman E. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett. 2011;305(2):163-174.
150. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn. 2008;10(4):279-292.
151. Sprangers B, Smets S, Sagaert X, et al. Posttransplant Epstein-Barr virusassociated myogenic tumors: case report and review of the literature. Am J Transplant. 2008;8(1):253-258.
152. Yan S, Jiang X, Yang J, Yan D, Wang YX. Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. Cancer Biother Radiopharm. 2012;27(8):519-523.
153. Gulley ML. Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn. 2001;3(1):1-10.
154. Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol. 2002;117(2):259-267.
155. Fanaian NK, Cohen C, Waldrop S, Wang J, Shehata BM. Epstein-Barr virus (EBV)-encoded RNA: automated in-situ hybridization (ISH) compared with manual ISH and immunohistochemistry for detection of EBV in pediatric lymphoproliferative disorders. Pediatr Dev Pathol. 2009;12(3):195-199.
156. Suh N, Liapis H, Misdraji J, Brunt EM, Wang HL. Epstein-Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients. Am J Surg Pathol. 2007;31(9):1403-1409.
157. Parkin RK, Boeckh MJ, Erard V, Huang ML, Myerson D. Specific delineation of BK polyomavirus in kidney tissue with a digoxigenin-labeled DNA probe. Mol Cell Probes. 2005;19(2):87-92.
158. Ventana Medical Systems. ISH iVIEW Blue Plus Detection Kit [package insert]. Basel, Switzerland: F. Hoffmann-La Roche; 2012. http://www.ventana. com/product/1349?type=1728. Accessed November 29, 2015.
159. Leica Biosystems. Bond Ready-To-Use Anti-Biotin Antibody [package insert]. Newcastle Upon Tyne, England: Leica Biosystems; 2014. http://www.leicabiosystems.com/fileadmin/img-uploads/novocastra-reagents/Novocastra-datasheets/ar0584.pdf. Accessed May 10, 2015.
160. Dako. In Situ Hybridization Detection System For Biotinylated Probes [package insert]. Carpinteria, CA: Dako North America; 2015. http://www.dako. com/us/download.pdf?objectid=127948001. Accessed June 11, 2015
161. Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med. 2007;131(8):1209-1218.
162. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:345-350. World Health Organization Classification of Tumours; vol 2.
163. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222-230.
164. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13(suppl 3):41-54.
165. Meru N, Davison S, Whitehead L, et al. Epstein-Barr virus infection in paediatric liver transplant recipients: detection of the virus in post-transplant tonsillectomy specimens. Mol Pathol. 2001;54(4):264-269.